Share on StockTwits

OncoGenex Pharmaceuticals (NASDAQ:OGXI) CMO Cindy Jacobs unloaded 5,650 shares of OncoGenex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $3.17, for a total transaction of $17,910.50. Following the completion of the sale, the chief marketing officer now directly owns 43,255 shares in the company, valued at approximately $137,118. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) traded down 0.46% on Friday, hitting $3.2847. 36,146 shares of the company’s stock traded hands. OncoGenex Pharmaceuticals has a 1-year low of $2.86 and a 1-year high of $14.25. The stock’s 50-day moving average is $3.24 and its 200-day moving average is $7.01. The company’s market cap is $69.4 million. OncoGenex Pharmaceuticals also saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 305,595 shares, a decrease of 45.7% from the July 15th total of 562,692 shares. Based on an average daily volume of 113,186 shares, the short-interest ratio is presently 2.7 days. Approximately 1.6% of the company’s shares are short sold.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.55) by $0.08. Analysts expect that OncoGenex Pharmaceuticals will post $-1.75 EPS for the current fiscal year.

OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.